Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech ( (EVAX) ) has shared an announcement.
On April 27, 2026, Evaxion A/S announced that Chief Scientific Officer Birgitte Rønø has been promoted to a dual role as both Chief Scientific Officer and Chief Operating Officer. The move follows an internal management review aimed at optimizing strategy execution and enhancing external visibility of the company’s AI-Immunology platform with partners and investors.
The expanded remit formally recognizes Rønø’s long-standing operational contributions and scientific expertise, consolidating scientific leadership and day-to-day operations under a single executive. Following the promotion, Evaxion’s core management team consists of CEO Helen Tayton-Martin, CSO/COO Birgitte Rønø, CFO Thomas Schmidt and Chief AI Officer Andreas Mattsson, a structure that underscores the company’s focus on integrating scientific, operational and AI capabilities as it advances its vaccine pipeline.
The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Denmark-based, clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The technology leverages artificial intelligence to decode the human immune system for rapid target discovery, drug design and development, supporting a pipeline of personalized and off-the-shelf vaccine candidates addressing high unmet medical needs.
Average Trading Volume: 39,784
Technical Sentiment Signal: Sell
Current Market Cap: $33.61M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.